Drug-Induced Acute Kidney Injury

Drug-induced nephrotoxicity is the third most common cause of acute kidney injury (AKI). The aim of the study was to analyse and summarise data on the factors and mechanisms responsible for increased risk of drug-induced AKI, to analyse potential methods of its prevention and treatment. At present, the following phenotypes of drug-induced AKI are distinguished: acute vascular disease, acute glomerular disease, acute tubular injury / necrosis, and acute interstitial nephritis. It was discovered that most often these complications occur following the use of antimicrobial drugs, renin-angiotensin-aldosterone system inhibitors, non-steroidal anti-inflammatory drugs, and anticancer drugs, including targeted therapy. Risk factors for drug-induced AKI include age >65, female gender, low body weight, pre-existing chronic kidney disease, hypovolemia, hypoalbuminemia, acute and chronic heart failure, diabetes, malignancies, liver cirrhosis, prolonged use of nephrotoxic drugs, and simultaneous use of two or more nephrotoxic drugs. Discontinuation of the drug which resulted in kidney failure is the first and foremost principle for managing not only drug-induced, but all AKI patients. The use of potentially nephrotoxic drugs should be avoided, especially in high-risk patients, in order to prevent drug-induced AKI. If a patient needs a drug that affects renal hemodynamics, the therapy should begin with a minimum effective dose, and combinations of two and more nephrotoxic drugs should be avoided. Close monitoring of kidney function is crucial for high-risk patients. They should also be informed about the importance of adequate water consumption schedule for prevention of hypovolemia.

1. Smirnov AV, Dobronravov VA, Rumyantsev AS, Shilov EM, Vatazin AV, Kayukov IG, et al. National guidelines acute kidney injury: basic principles of diagnosis, prevention and therapy. Part I. Nefrologiya = Nephrology (Saint-Petersburg). 2016;20(1):79–104 (In Russ.)

2. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–126. https://doi.org/10.1038/kisup.2012.8

3. Ghane SF, Assadi F. Drug-induced renal disorders. J Renal Inj Prev. 2015;4(3):57–60. https://doi.org/10.12861/jrip.2015.12

4. Sales G, Foresto R. Drug-induced nephrotoxicity. Rev Assoc Med Bras. 2020;66(Suppl. 1):82–90. https://doi.org/10.1590/1806-9282.66.S1.82

5. Petejova N, Martinek A, Zadrazil J, Teplan V. Acute toxic kidney injury. Ren Fail. 2019;41(1):576–94. https://doi.org/110.1080/0886022X.2019.1628780

6. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–6. https://doi.org/10.1053/ajkd.2002.32766

7. Schetz M, Dasta J, Goldstein S, Golper T. Drug induced acute kidney injury. Curr Opin Crit Care. 2005;11(6):555–65. https://doi.org/10.1097/01.ccx.0000184300.68383.95

8. Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, Macleod A. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol. 2007;18(4):1292–8. https://doi.org/10.1681/ASN.2006070756

9. Wang HE, Muntner P, Chertow GM, Warnock DG. Acute kidney injury and mortality in hospitalized patients. Am J Nephrol. 2012;35(4):349–55. https://doi.org/10.1159/000337487

10. Thakar CV, Christianson A, Freyberg R, Almenoff P, Render M. Incidence and outcomes of acute kidney injury in intensive care units: a Veterans Administration study. Crit Care Med. 2009;37(9):2552–8. https://doi.org/10.1097/ccm.0b013e3181a5906f

11. Smirnov AV, Rumyantsev ASh. Acute kidney disease. Part I. Nefrologiya = Nephro­logy (Saint-Petersburg). 2020;24(1):67–95 (In Russ.) https://doi.org/10.36485/1561-6274-2020-24-1-67-95

12. Kane-Gill SL, Goldstein SL. Drug-induced acute kidney injury: a focus on risk assessment for prevention. Crit Care Clin. 2015;31(4):675–84. https://doi.org/10.1016/j.ccc.2015.06.005

13. Ympa YP, Sakr Y, Reinhart K, Vincent JL. Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med. 2005;118(8):827–32. https://doi.org/10.1016/j.amjmed.2005.01.069

14. Gruberg L, Weissman NJ, Pichard AD, Waksman R, Kent KM, Satler LF, et al. Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. Am Heart J. 2003;145(3):529–34. https://doi.org/10.1067/mhj.2003.121

15. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–8. https://doi.org/10.1001/jama.294.7.813

16. Anathhanam S, Lewington AJP. Acute kidney injury. J R Coll Physicians Edinb. 2013;43(4):323–8. https://doi.org/10.4997/jrcpe.2013.412

17. Mehta RL, Awdishu L, Davenport A, Murray P, Macedo E, Cerda J, et al. Phenotype standardization for drug-induced kidney disease. Kidney Int. 2015;88(2):226–34. https://doi.org/10.1038/ki.2015.115

18. Izzedine H, Perazella MA. Anticancer drug-induced acute kidney injury. Kidney Int Rep. 2017;2(4):504–14. https://doi.org/10.1016/j.ekir.2017.02.008

19. Perazella MA. Update on the renal effects of anticancer agents. J Onco-Nephrol. 2017;1(3):170–8. https://doi.org/10.5301/jo-n.5000026

20. Chemotherapy and radiation related kidney diseases. In: Finkel KW, Perazella MA, Cohen EP, eds. Onco-Nephrology. Elsevier; 2020. Section 4. P. 127–96.

21. Paueksakon P, Fogo AB. Drug-induced nephropathies. Histopathology. 2017;70(1):94–108. https://doi.org/10.1111/his.13064

22. Jackson B, Matthews PG, McGrath BP, Johnston CI. Angiotensin converting enzyme inhibition in renovascular hypertension: frequency of reversible renal failure. Lancet. 1984;1(8370):225–6. https://doi.org/10.1016/s0140-6736(84)92149-4

23. Mason NA. Angiotensin-converting enzyme inhibitors and renal function. DICP. 1990;24(5):496–505. https://doi.org/10.1177/106002809002400511

24. Whelton A, Hamilton CW. Non-steroidal anti inflammatory drugs: effects on kidney function. Clin Pharmacol. 1991;31(7):588–98. https://doi.org/10.1002/j.1552-4604.1991.tb03743.x

25. Goli R, Mukku KK, Devaraju SB, Uppin MS. Acyclovir-induced thrombotic microangiopathy. Indian J Nephrol. 2017;27(2):131–2. https://doi.org/10.4103/0971-4065.181453

26. Rey A, Batteux B, Laville SM, Marienne J, Masmoudi K, Gras-Champel V, Liabeuf S. Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study. Arthritis Res Ther. 2019;21(1):229. https://doi.org/10.1186/s13075-019-2011-y

27. Leowattana W. Antiviral drugs and acute kidney injury (AKI). Infect Disord Drug Targets. 2019;19(4):375–82. https://doi.org/10.2174/1871526519666190617154137

28. Kim YG, Kim B, Kim MK, Chung SJ, Han HJ, Ryu JA, et al. Medullary nephrocalcinosis associated with long-term furosemide abuse in adults. Nephrol Dial Transplant. 2001;16(12):2303–9. https://doi.org/10.1093/ndt/16.12.2303

29. Gagnon RF, Mehio A, Iqbal S, Tsoukas CM. Néphropathie tubulo-interstitielle associée à l’indinavir. Nephrol Ther. 2007;3(7):461–2. https://doi.org/10.1016/j.nephro.2007.07.004

30. Wu D, Stoller ML. Indinavir urolithiasis. Curr Opin Urol. 2000;10(6):557–61. https://doi.org/10.1097/00042307-200011000-00004

31. Lamb EJ, Nashef L, Stevens PE. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem. 2004;41(Pt 2):166–9. https://doi.org/10.1258/000456304322880104

32. de la Prada Alvarez FJ, Prados Gallardo AM, Tugores Vázquez A, Uriol Rivera M, Morey Molina A. Insuficiencia renal aguda por depósito de cristales de Sulfadiacina. An Med Interna. 2007;24(5):235–8.

33. Kubota M, Nishi-Nagase M, Sakakihara Y, Noma S, Nakamoto M, Kawaguchi H, et al. Zonisamide-induced urinary lithiasis in patients with intractable epilepsy. Brain Dev. 2000;22(4):230–3. https://doi.org/10.1016/s0387-7604(00)00118-2

34. Ram R, Swarnalatha G, Prasad N, Prayaga A, Dakshina Murthy KV. Granulomatous interstitial nephritis after prolonged use of phenytoin. Saudi J Kidney Dis Transpl. 2009;20(1):131–3.

35. Torregrosa E, Rovira RE, Calvo C, Hernández-Jaras J, Maduell F, García H. Nefritis intersticial aguda por omeprazol. Nefrologia. 2004;24 Suppl 3:61–3.

36. Muthukumar T, Jayakumar M, Fernando EM, Muthusethupathi M. Acute renal failure due to rifampicin: a study of 25 patients. Am J Kidney Dis. 2002;40(4):690–6. https://doi.org/10.1053/ajkd.2002.35675

37. Enríquez R, Cabezuelo JB, González C, Lacueva J, Teruel A, Fernández J, Arenas MD. Granulomatous interstitial nephritis associated with hydrochlorothiazide/amiloride. Am J Nephrol. 1995;15(3):270–3. https://doi.org/10.1159/000168845

38. Yoshikawa H, Watanabe T, Abe T. Tubulo-interstitial nephritis caused by sodium valproate. Brain Dev. 2002;24(2):102–5. https://doi.org/10.1016/s0387-7604(02)00007-4

39. Tisdale JE, Miller DA, eds. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018.

40. Derungs A. Medikamentös bedingte akute Nierenschädigung. Ther Umsch. 2015;72(11–12):717–27. https://doi.org/10.1024/0040-5930/a000742

41. Postnikov SS, Gratsianskaya AN, Kostyleva MN. Drug-induced kidney injury. Pediatriya = Pediatria. 2016;95(4):167–73 (In Russ.)

42. Reddy VG. Prevention of postoperative acute renal failure. J Postgrad Med. 2002;48(1):64–70.

43. Venkataraman R. Can we prevent acute kidney injury? Crit Care Med. 2008;36(4 Suppl.):166–71. https://doi.org/10.1097/ccm.0b013e318168c74a

44. Stewart J, Findlay G, Smith N, Kelly K, Mason M. Adding Insult to Injury: A Review of the Care of Patients Who Died in Hospital with a Primary Diagnosis of Acute Kidney Injury (Acute Renal Failure). London: NCEPOD; 2009.

45. Cerda J, Bagga A, Kher V, Chakravarthi R. The contrasting characteristics of acute kidney injury in developed and developing countries. Nat Clin Pract Nephrol. 2008;4(3):138–53. https://doi.org/10.1038/ncpneph0722

46. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685–93. https://doi.org/10.1001/archinte.160.5.685

47. Smirnov AV, Dobronravov VA, Rumyantsev AS, Shilov EM, Vatazin AV, Kayukov IG, et al. National guidelines acute kidney injury: basic principles of diagnosis, prevention and therapy. Part II. Nephrologiya = Nephrology (Saint-Petersburg). 2016;20(2):86–100 (In Russ.)

48. Bidulka P, Fu EL, Leyrat C, Kalogirou F, McAllister KSL, Kingdon EJ, et al. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care. BMC Med. 2020;18(1):195. https://doi.org/10.1186/s12916-020-01659-x

49. Hsu CY, Liu KD, Yang J, Glidden DV, Tan TC, Pravoverov L, et al. Renin-angiotensin system blockade after acute kidney injury (AKI) and risk of recurrent AKI. Clin J Am Soc Nephrol. 2020;15(1):26–34. https://doi.org/10.2215/CJN.05800519

50. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum. 2002;32(3 Suppl 1):33–42. https://doi.org/10.1053/sarh.2002.37216

51. Graham MG. Acute renal failure related to high-dose celecoxib. Ann Intern Med. 2001;135(1):69–70. https://doi.org/10.7326/0003-4819-135-1-200107030-00038

52. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis. 2000;35(5):937–40. https://doi.org/10.1016/s0272-6386(00)70266-6

53. Evsiutina EP, Dinikina YuV, Belogurova MB, Aleksandrovich YuS. Prevention of toxicity in chemotherapy with high doses of methotrexate in children. Pediatr = Pediatrician (St. Petersburg). 2019;10(2):89–98 (In Russ.) https://doi.org/10.17816/PED10289-98

54. Gromova EG, Biryukova LS, Dzhumabaeva BT, Kurmukov IA. Practical recommendations for the correction of nephrotoxicity of antitumor drugs. Zlokachestvennye opukholi. Prakticheskie rekomendatsii RUSSCO = Malignant tumors. Practical recommendations RUSSCO. 2020;10(3s2):118–30 (In Russ.) https://doi.org/10.18027/2224-5057-2020-10-3s2-46

55. Widemann BC, Schwartz S, Jayaprakash N, Christensen R, Pui CH, Chauhan N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy. 2014;34(5):427–39. https://doi.org/10.1002/phar.1360

56. Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis. 2015;66(5):857–68. https://doi.org/10.1053/j.ajkd.2015.02.340

57. Perazella MA, Sprangers B. AKI in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(7):1077–9. https://doi.org/10.2215/CJN.02340219

58. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev. 2016;30(3):157–67. https://doi.org/10.1016/j.blre.2015.10.003

59. Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457–68. https://doi.org/10.2147/ijnrd.s39747

60. Acute renal failure of medicinal origin. Section 1. Overview information. Bezopasnost’ lekarstv = Drug Safety. 2000;(1):31–8 (In Russ.)

61. Thomas MC. Diuretics, ACE inhibitors and NSAIDs — the triple whammy. Med J Aust. 2000;172(4):184–5. https://doi.org/10.5694/j.1326-5377.2000.tb125548.x

62. Muravyev YuV. How is folic acid to be used in rheumatoid arthritis during methotrexate treatment? Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):201–4 (In Russ.) https://doi.org/10.14412/1995-4484-2013-649

63. Cosmai L, Porta C, Foramitti M, Perrone V, Mollica L, Gallieni M, Capasso G. Preventive strategies for acute kidney injury in cancer patients. Clin Kidney J. 2020;14(1):70–83. https://doi.org/10.1093/ckj/sfaa127

64. Zakharova EV, Ostroumova OD. Onco-nephrology: anti-cancer drug-induced kidney damage. Review of literature — part 1. Nefrologiya i dializ = Nephrology and Dialysis. 2020;22(3):383–95 (In Russ.) https://doi.org/10.28996/2618-9801-2020-3-383-395